OptimizeRx Corporation (OPRX)
| Market Cap | 120.83M -22.0% |
| Revenue (ttm) | 109.43M +18.8% |
| Net Income | 5.13M |
| EPS | 0.27 |
| Shares Out | 18.76M |
| PE Ratio | 23.85 |
| Forward PE | 6.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 232,420 |
| Open | 6.57 |
| Previous Close | 6.63 |
| Day's Range | 6.30 - 6.57 |
| 52-Week Range | 5.54 - 22.25 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 16.67 (+158.85%) |
| Earnings Date | May 12, 2026 |
About OPRX
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OPRX stock is "Strong Buy." The 12-month stock price target is $16.67, which is an increase of 158.85% from the latest price.
News
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthca...
OptimizeRx Appoints Mary Varghese Presti to Board of Directors
Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency Microsoft Health & Life Sciences COO brings ...
OptimizeRx trading halted, volatility trading pause
09:31 EST OptimizeRx (OPRX) trading halted, volatility trading pause
OptimizeRx price target lowered to $20 from $24 at Lake Street
Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $20 from $24 and keeps a Buy rating on the shares. While “disappointed” with the lowered revenue outlook for
OptimizeRx price target lowered to $11 from $28 at B. Riley
B. Riley analyst Anderson Schock lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $28 and keeps a Buy rating on the shares. The firm views the company’s
OptimizeRx price target lowered to $18 from $32 at Roth Capital
Roth Capital lowered the firm’s price target on OptimizeRx (OPRX) to $18 from $32 and keeps a Buy rating on the shares after it’s below-consensus revenue guidance. Revenue weakness rapidly
OptimizeRx price target lowered to $17 from $21 at Stifel
Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $17 from $21 and keeps a Buy rating on the shares. A challenged environment is reflected in guidance, though this
OptimizeRx price target lowered to $10 from $17 at Stephens
Stephens analyst Jeff Garro lowered the firm’s price target on OptimizeRx (OPRX) to $10 from $17 and keeps an Equal Weight rating on the shares despite a “big” Q4 EBITDA
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Earnings Call Transcript: Q4 2025
Q4 and FY 2025 results exceeded expectations with strong revenue, margin, and cash flow growth, driven by both large and mid-tier clients. 2026 guidance is more conservative due to market shifts and cautious client spending, but profitability focus and new partnerships support long-term optimism.
OptimizeRx reports Q4 EPS 51c, consensus 22c
Reports Q4 revenue $32.24M, consensus $30.91M. Stephen Silvestro, OptimizeRx (OPRX) CEO commented, “We delivered a strong fourth quarter, exceeding both consensus and internal expectations, with reven...
OptimizeRx sees FY26 revenue $109M-$114M, consensus $121.63M
Sees FY26 adjusted EBITDA $21M-$25M. The company said, “We are beginning to see increased market volatility, driven in part by uncertainty surrounding Most Favored Nation pricing. In response, we beli...
OptimizeRx announces $10M share repurchase program
OptimizeRx’s (OPRX) board of directors has authorized a share repurchase program for up to $10M of the company’s outstanding common stock. This share repurchase authorization is effective March 12 and
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx management to meet with Lake Street
Meeting to be held in Boston on March 11 and in New York on March 12 hosted by Lake Street.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx announces data collaboration with Experian
OptimizeRx (OPRX) announced at CES 2026 a data collaboration with Experian (EXPGY). This integration maps OptimizeRx Micro-Neighborhood audiences to Experian’s identity graph, “enabling seamless onboa...
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage...
OptimizeRx announces four new partner agreements
OptimizeRx (OPRX) announced four new partner agreements that expand the company’s in-workflow point-of-care network. The newly executed agreements include: an exclusive, multi-year agreement with a e-...
OptimizeRx Continues Expansion of the Company's Point-Of-Care Network
WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx price target lowered to $17 from $20 at Stephens
Stephens analyst Jeff Garro lowered the firm’s price target on OptimizeRx (OPRX) to $17 from $20 and keeps an Equal Weight rating on the shares. Noting that shares are up
OptimizeRx price target raised to $21 from $18 at Stifel
Stifel analyst David Grossman raised the firm’s price target on OptimizeRx (OPRX) to $21 from $18 and keeps a Buy rating on the shares. Revenue for the quarter materially outperformed,
OptimizeRx price target raised to $32 from $27 at Roth Capital
Roth Capital raised the firm’s price target on OptimizeRx (OPRX) to $32 from $27 and keeps a Buy rating on the shares. The company reported strong Q3 results and beat